Davos 2026 Marks a Milestone for Longevity and Frontier Investments 
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
TEL AVIV, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in...
CytoDyn Announces Resolution of Class Action Lawsuit
VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company...
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZSAN DIEGO and...
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company...
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. , a global leader in cellular and cell-derived therapeutics for the...
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on...
Mixie Technologies, Inc. (OTC: PHCG) formerly known as Pure Harvest Corporate Group, Executes Binding Letter of Intent to Acquire Minority Interest in HoloTwin LLC
Introduces AI-driven digital twin visualization capabilities aligned with Mixie’s evolution into a technology and platform focused enterpriseDENVER, Dec. 01, 2025...
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals...
Johnson & Johnson receives European Commission approval of IMAAVY® (nipocalimab), a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG)
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are...
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially...
NRx Pharmaceuticals (NASDAQ:NRXP) and HOPE Therapeutics to Present at NobleCon21 – Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference
WILMINGTON, Del., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company...
ProQR to Participate in 8th Annual Evercore Healthcare Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated...
Philips expands commercial availability of world’s first real-time AI-enabled light-based 3D navigation solution for image-guided therapy
Philips LumiGuide 3D device guidance in use Philips LumiGuide 3D device guidance in use December 1, 2025 Commercial availability expanded...
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route...
Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity Conference
BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James...
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology...
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer’s Patients
Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation...
Connect Strengthens Leadership Team with Promotion of Cait Kelly to Chief Strategy Officer
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Connect, the premier nonprofit organization in San Diego’s innovation ecosystem dedicated to...
Zwanger-Pesiri Radiology Implements Konica Minolta Healthcare’s Bone Suppression Imaging Technology to Enhance Chest X-ray Diagnoses
Konica Minolta Healthcare Bone Suppression Imaging Bone Suppression Imaging from Konica Minolta suppresses the ribs and the clavicle from standard...
Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference
BOSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment...